Kite discovered Tecartus™ (brexucabtageneautoleucel, formerly KTE-X19), a novel Chimeric Antigen Receptor (CAR) T for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (MCL).
Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy suitable for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Hence, the newly approved CAR T cell therapy for mantle cell lymphoma patients indicates a new frontier in the treatment of this disease.
MCL is a rare type of cancerous B-cell non-Hodgkin lymphoma that typically grows from cells that reside in the lymph nodes mantle region and mainly affecting middle-aged or older adults.Most of the patients experience frequent relapse after initial treatment and moreover the cause of MCL is unknownand at the same time it is incurable.
Some of the adverse symptomsof patients with MCL include painless swelling in the armpit, neck or groin region, unexplained weight loss, night sweats, fever with no obvious cause, anaemia, diarrhoea, loss of appetite, sickness (nausea) and easy bruising or bleeding.
U.S.Food and Drug Administration (FDA) grants Tecartus™ (brexucabtageneautoleucel, formerly KTE-X19) the first and only approved CAR T cell therapy for treating relapsed or refractory mantle cell lymphoma (r / r MCL).
